Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

• Hauptverfasser: Masoud Etemadifar (Verfasst von), Amir Parsa Abhari (Verfasst von), Hosein Nouri (Verfasst von), Amirhossein Akhavan Sigari (Verfasst von), Seyed Mohammad Piran Daliyeh (Verfasst von), Mohammad Reza Maracy (Verfasst von), Mehri Salari (Verfasst von), Shiva Maleki (Verfasst von), Nahad Sedaghat (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. 16.2% of the vaccinated pwMS reported at least one neurological symptom in their respective vaccine-related at-risk p...